Integra LifeSciences (IART) Tops Q1 EPS by 14c ; Offers Guidance

Integra LifeSciences (NASDAQ: IART) reported Q1 EPS of $0.54, $0.14 better than the analyst estimate of $0.40. Revenue for the quarter came in at $391.9 million versus the consensus estimate of $381.81 million.

GUIDANCE:

Integra LifeSciences sees FY2026 EPS of $2.40-$2.50, versus the consensus of $2.35. Integra LifeSciences sees FY2026 revenue of $1.66-1.71 billion, versus the consensus of $1.67 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Goldman Sachs (GS) Reiterated at Market Perform by Citizens on Constructive Backdrop
• Starwood Property Trust (STWD) Reiterated at Market Outperform by Citizens
• Jefferies Financial Group (JEF) Misses Q2 EPS by 22c